Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report.

IF 3.4 3区医学 Q2 HEMATOLOGY

Therapeutic Advances in Hematology Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI:10.1177/20406207241270846

Gaia Ciolli, Andrea Pasquini, Francesco Mannelli, Barbara Scappini, Giacomo Gianfaldoni, Elisa Quinti, Laura Fasano, Jessica Caroprese, Francesca Crupi, Alessandro Maria Vannucchi, Matteo Piccini

{"title":"Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report.","authors":"Gaia Ciolli, Andrea Pasquini, Francesco Mannelli, Barbara Scappini, Giacomo Gianfaldoni, Elisa Quinti, Laura Fasano, Jessica Caroprese, Francesca Crupi, Alessandro Maria Vannucchi, Matteo Piccini","doi":"10.1177/20406207241270846","DOIUrl":null,"url":null,"abstract":"Polyethylene-glycolated Escherichia coli-derived l-asparaginase (pegaspargase, pASP) is an essential component of paediatric-inspired regimens for the treatment of acute lymphoblastic leukaemia/lymphoma; nonetheless, is characterised by severe and potentially life-threatening toxicities, such as hypertriglyceridemia. Grades 3-4 events have been reported in ~1%-18% of paediatric patients and in sparse reports in adults. There is limited evidence on the safety of asparaginase rechallenge in patients experiencing severe pASP-related hypertriglyceridemia. Herein we present the case of a young adult patient diagnosed with T-LBL who experienced an asymptomatic severe pASP-related hypertriglyceridemia and was safely re-exposed to ASP using Erwinia chrysanthemi asparaginase (crisantapase), with only mild transient hypertriglyceridemia recurrence.","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425753/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207241270846","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Polyethylene-glycolated Escherichia coli-derived l-asparaginase (pegaspargase, pASP) is an essential component of paediatric-inspired regimens for the treatment of acute lymphoblastic leukaemia/lymphoma; nonetheless, is characterised by severe and potentially life-threatening toxicities, such as hypertriglyceridemia. Grades 3-4 events have been reported in ~1%-18% of paediatric patients and in sparse reports in adults. There is limited evidence on the safety of asparaginase rechallenge in patients experiencing severe pASP-related hypertriglyceridemia. Herein we present the case of a young adult patient diagnosed with T-LBL who experienced an asymptomatic severe pASP-related hypertriglyceridemia and was safely re-exposed to ASP using Erwinia chrysanthemi asparaginase (crisantapase), with only mild transient hypertriglyceridemia recurrence.

查看原文本刊更多论文

在使用天冬酰胺酶诱发高甘油三酯血症后，成功地重新挑战了埃尔温氏菌天冬酰胺酶：一份病例报告。

聚乙二醇化大肠杆菌衍生的 l-天冬酰胺酶（pegaspargase，pASP）是治疗急性淋巴细胞白血病/淋巴瘤的儿科启发方案的重要组成部分；然而，该药物具有严重且可能危及生命的毒性，如高甘油三酯血症。据报道，约有 1%-18%的儿科患者发生过 3-4 级事件，成人患者中也有少量报道。对于出现严重 pASP 相关高甘油三酯血症的患者，有关天冬酰胺酶再挑战安全性的证据有限。在此，我们介绍了一例被诊断为 T-LBL 的年轻成人患者的病例，该患者经历了无症状的严重 pASP 相关高甘油三酯血症，使用 Erwinia chrysanthemi 天冬酰胺酶（crisantapase）对其进行了安全的 ASP 再接触，仅有轻微的一过性高甘油三酯血症复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Hematology HEMATOLOGY-

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

7 weeks

期刊介绍： Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.